Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568009 · ClinicalTrials.gov registry record
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
A clinical trial, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- 300
- Enrollment target
NCT00568009 is a clinical trial that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 300 participants.
The verdict
NCT00568009 was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- 300 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of SLV320 or placebo in a sequential fashion.
Interventions
- DRUG SLV320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568009
The ClinicalTrials.gov registry entry for NCT00568009 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SLV320 is the first listed.
NCT00568009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00568009 about?
NCT00568009 is a clinical study titled "Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function". This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of...
What is the current status of trial NCT00568009?
This trial is currently terminated. The enrollment target is 300 participants. The study started on 2007-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00568009?
The interventions under investigation include: SLV320 (DRUG).
Who is sponsoring clinical trial NCT00568009?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.